acetylcysteine injection, solution
stelis biopharma limited - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions ( 5.1 )] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background r
acetylcysteine injection, solution
xellia pharmaceuticals usa llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)]. risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and misc
acetylcysteine solution usp
sterimax inc - acetylcysteine - solution - 200mg - acetylcysteine 200mg
acetylcysteine injection solution
teligent ou - acetylcysteine - solution - 200mg - acetylcysteine 200mg - antidotes
omegapharm acetylcysteine 800 mg/4 ml acetylcysteine solution for inhalation vial
omegapharm - acetylcysteine, quantity: 800 mg - solution - excipient ingredients: hydrochloric acid; water for injections; disodium edetate; sodium hydroxide - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).
dbl acetylcysteine injection concentrate acetylcysteine 2 g/ 10 ml injection ampoule
pfizer australia pty ltd - acetylcysteine, quantity: 2 g - injection, concentrated - excipient ingredients: water for injections; disodium edetate; sodium hydroxide - as an antidote for paracetamol poisoning: acetylcysteine injection concentrate is indicated in the treatment of paracetamol overdose to protect against hepatotoxicity.
omegapharm acetylcysteine 2000 mg/ 10 ml acetylcysteine solution for inhalation vial
omegapharm - acetylcysteine, quantity: 2000 mg - solution - excipient ingredients: disodium edetate; sodium hydroxide; water for injections; hydrochloric acid - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).
acetylcysteine sandoz effervescent tablet 600mg
sandoz products malaysia sdn. bhd. - acetylcysteine -
acetylcysteine sandoz effervescent tablet 200mg
sandoz products malaysia sdn. bhd. - acetylcysteine -
acetylcysteine injection solution
auro pharma inc - acetylcysteine - solution - 200mg - acetylcysteine 200mg